Milestone Pharmaceuticals shares jumped nearly 32% after the FDA approved Cardamyst, its first commercial product for treating paroxysmal supraventricular tachycardia. The self-administered nasal spray targets a market of over two million Americans and is expected to reach retail pharmacies in early 2026.